Michael A. Holinstat, Ph.D. Recognized as Recipient of the 2024 ACTS Distinguished Educator: Mentorship Innovation Award
The Association for Clinical and Translational Science (ACTS), a non-profit membership association of translational scientists from the nation’s leading academic medical centers, honored its Translational Science Award recipients at Translational Science 2024.
MICHR is pleased to announce that Michael A. Holinstat, Ph.D., director of MICHR’s Predoctoral T32 training grant in clinical research, was recognized as a recipient of the 2024 ACTS Distinguished Educator: Mentorship Innovation Award.
Dr. Holinstat is a professor in the Departments of Pharmacology, Internal Medicine and Surgery at the University of Michigan Medical School and a fellow of the American Heart Association.
His research interests focus on understanding lipid, lipoxygenase, and oxygenase regulation of platelet signaling and function and how it relates to regulation of hemostasis and thrombosis.
Dr. Holinstat serves on several national boards including the sub-committee on Hemostasis and Thrombosis at the American Society for Hematology.
He has received several national awards including the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the Council on Arteriosclerosis, Thrombosis, and Vascular Biology in 2012 and the Young Investigator Award in Structure-Function from the Eicosanoid Research Foundation in 2013.
In addition to his NIH-funded research, Dr. Holinstat continues to translate his discoveries into potential clinical applications through collaborations with Veralox Therapeutics, Cereno Scientific, and Lexicon Pharmaceuticals.
Dr. Holinstat has spent the last 20 years training the next generation of clinical and translational scientists in the area of blood clotting, platelet biochemistry, and discovery of novel therapeutic approaches for treating thrombosis including undergraduates, graduate students, postdoctoral fellows, clinical fellows, and basic and clinical faculty.
ACTS presents its annual Translational Science Awards to recognize investigators for their outstanding contributions to the clinical research and translational science field. Individuals and teams are nominated by their colleagues and peers and may be selected from all industry segments.
“The ACTS awards recognize talented investigators who translate their findings ultimately from the bench to the community. Awardees are in all phases of studies and disciplines throughout the workforce which includes investigators, trainees, educators, and research teams. We also advance the principles of diversity, inclusion and health equity”, said ACTS President Linda B Cottler, PhD, MPH, FACE. “These award winners and their work represent the values and mission of ACTS and we are happy to celebrate their achievements at Translational Science 2024.”
The ACTS Distinguished Educator: Mentorship Innovation Award recognizes distinguished mentors with outstanding innovation in mentorship resulting in significant scientific accomplishments by the next generation of clinical and translational researchers and/or innovative approaches in mentorship to promote diversity and retention of under-represented groups in translational research.